Privia Health Group, Inc. PRVA 深 沪
已收盘 03-27 16:00:00 美东时间
20.02
-0.160
-0.79%
华盛通- 最 高20.15
- 今 开19.97
- 成交量 96.90万股
- 最 低 19.53
- 昨 收 20.18
- 总市值 24.82亿
- 52周最高 26.51
- 市盈率 静 112.60
- 换手率 0.78%
- 52周最低 18.77
- 委 比 -54.06%
- 总股本 1.24亿
- 历史最高 50.77
- 量 比 1.04
- 振 幅 3.07%
- 历史最低 15.92
- 每 手 1
- 风险率 1.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高240美元，潜在涨幅53%！ARM获多家大行上调目标价；Braze 评级上演 “两极反转”，小摩、巴克莱上调，高盛、花旗下调
今日重点评级关注：HC Wainwright & Co.：维持OCUGEN"买入"评级，目标价从7美元升至10美元；HC Wainwright & Co.：维持Maze Therapeutics"买入"评级，目标价从60美元升至110美元
03-26 11:41
Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $25
Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:PRVA) with a Equal-Weight and raises the price target from $23 to $25.
03-25 21:26
Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
Privia Health Group has been awarded the 2026 MAP Award for High Performance in Revenue Cycle by HFMA, recognizing its sustained excellence in key metrics. This is the ninth time in ten years the company has received this distinction. Privia's achievement reflects its commitment to innovation, disciplined operations, and patient-centered practices. The award was presented during the HFMA Revenue Cycle Conference in Arlington, Texas. Privia's succ...
03-24 13:00
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Privia Health Group shares are trading higher after the company reported better-than-expected Q4 adjusted EPS results.
Privia Health Group shares are trading higher after the company reported better...
02-27 00:20
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Privia Health Gr Earnings Report: Q4 Overview
The Q4 earnings report for Privia Health Gr (NASDAQ:PRVA) was released on Thurs...
02-26 19:04
Privia Health Gr Sees FY2026 Sales $2.350B-$2.450B vs $2.380B Est
Privia Health Gr (NASDAQ:PRVA) sees FY2026 sales of $2.350 billion-$2.450 billion vs $2.380 billion analyst estimate.
02-26 19:04
Privia posts FY 2025 operating income of USD 34.2 million, up 101.6%
Privia posts FY 2025 operating income of USD 34.2 million, up 101.6% Privia Health reported Q4 2025 revenue of USD 541.2 million (+17.4%) and net income of USD 9.2 million (+108.0%), with adjusted EBITDA of USD 31.5 million (+26.4%). For FY 2025, Privia Health posted revenue of USD 2.1 billion (+22.
02-26 19:03
